Reducing the cost of screening novel agents using the hollow fibre assay.
Although the in vivo hollow fibre assay (HFA) as utilised by the National Cancer Institute is a highly effective screening tool, it has not been adopted en masse in the cancer pharmacology field. However, in laboratories which have adopted it, the effectiveness of HFA has also been confirmed. If immunocompetent mice could be used with the HFA, thereby reducing the cost of the assay, accessibility would increase and reductions in the cost of selecting appropriate agents for early clinical trials would result. It was demonstrated here that there was no difference in terms of cell growth and response to chemotherapy for cancer cells in hollow fibres in immunocompetent compared with immunodeficient mice. The HFA can thus be performed in these less expensive and more easily available mice with the implication of considerable savings to the preclinical cancer pharmacology community.
Shnyder
S D
SD
Institute of Cancer Therapeutics, School of Health Studies, University of Bradford, Bradford BD7 1DP, UK. S.D.Shnyder@Bradford.ac.uk
Cooper
P A
PA
Scally
A J
AJ
Bibby
M C
MC
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology; D004317:Doxorubicin / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor / Q000191:economics* / Q000379:methods*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D017239:Paclitaxel / Q000494:pharmacology
D004317:Doxorubicin; D017239:Paclitaxel